Hemorrhage Treatment Report of Patients Suffering from Glanzmann’s Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children’s Hospital
Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 6, Issue 3
Abstract
Background: The present study evaluated treatment outcomes and the treatment indexes among Glanzmann’s patients in Mofid Children’s Hospital, Tehran, Iran. Patients and Methods: A retrospective cross-sectional study was performed to evaluate the treatment protocols on 15 Glanzmann’s patients with bleeding therapeutic records in Mofid Children’s Hospital, Tehran, Iran, from 2006 to 2011. Results: The total recombinant factor VIIa used was 137mg and the total infused platelet concentrates was 68 units, with platelets used in order being: apheresis platelets, leukoreduced pooled platelets, leukoreduced platelets, and random donor platelets with 35, 16, 13 and 4 units respectively. In 90% of bleeding sequences, leukoreduced platelets were available and the average admission per patient was 3.46 times, the average leukoreduced platelets consumption per patient was 4.26 units and the average use of recombinant factor VIIa per patient was 9.13mg. Other Indexes included the average hospitalization per patient per year of 0.69% times, the average consumption of non- random platelet per patient per year of 0.85% units, the average consumption of recombinant factor VIIa per patient per year of 1.83mg, the average consumption of non random platelet for any hemorrhage incidence or elective surgery of 1.3 units, and the average consumption of recombinant factor VIIa for any hemorrhage incidence of 2.8mg. Conclusion: By extracting the consumption of therapeutical products to treat Glanzmann’s thrombasthenia in our center we could estimate the future treatment needs of our medical center. More thorough investigation of patients from different age groups is recommended to achieve more reliable results. Key Words: Glanzmann’s thrombasthenia, platelet, rFVIIa, treatment index.
Authors and Affiliations
Peyman Eshghi, Alireza Jenabzadeh, Behnaz Habibpanah
Keywords
Related Articles
- EP ID EP364642
- DOI -
- Views 78
- Downloads 0
Main Determinants of Severe Neutropenia in Patients with Solid Tumors Receiving Adjuvant Chemotherapy
Background:Chemotherapy-induced neutropenia as a major toxicity of systemic chemotherapy is commonly associated with substantial mortality and morbidity, and thus identifying its determinants is necessary. This study was...
Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta- thalassemia Major in Iran; A Non-randomized Controlled Trial
Background: Iron chelators are an important part of management of patients with thalassemia. It is prudent to compare efficacy of different iron chelators in treatment of iron overload in these patients who receive regul...
In vitro Evaluation of the antibacterial activity of Platelet-rich Plasma against Selected Oral and Periodontal Pathogens
Background: Despite the availability of a wide range of antibiotics, bacterial infections are among important challenges for the healthcare system. Therefore, the introduction of new antimicrobial preparations such as pl...
Neuroblastoma Associated with Bilateral Ptosis: Report of a Rare Condition
Neuroblastoma is a common tumor in pediatric cancer and which might present with usual or unusual clinical features. One of the rare clinical finding of neuroblastoma is paraneoplastic syndromes. We report a two year-old...
Association of Acute Lymphoblastic Leukemia and MDR1 Gene Polymorphism in an Ethnic Iranian Population
Background: The frequency of the multi-drug resistance 1 (MDR1) gene C3435T polymorphism differs in various ethnical populations such as Asian, African, and Caucasians populations. A silent C3435T polymorphism in exon 26...